AtaiBeckley
About
AtaiBeckley is a global leader in the development of transformative mental health therapies, formed through the strategic combination of atai Life Sciences and Beckley Psytech in November 2025. The company is dedicated to developing innovative psychedelic-based neuroplastogens and related therapeutics to treat mental health disorders, including treatment-resistant depression and social anxiety disorder.
Key facts
At-a-glance profile data
- Website
- ataibeckley.com
- Headquarters
- New York, United States
- Founded
- 2018
- Employees
- 95
- Total funding
- $640M (Merger)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 5 Nov 2025 | Merger | $390M | - |
| 1 Oct 2025 | Public Offering | $150M | - |
| 1 Jul 2025 | Private Placement | $50M | Christian Angermayer’s Apeiron Investment Group |
| 5 Jan 2024 | Strategic Investment | $50M | - |
Tech stack
Detected on ataibeckley.com, last scanned 19 Sept 2026. Run your own scan
- Frontend
- Next.js, Tailwind CSS
- CDN
- Vercel
- Email provider
- Mimecast
- Video / media
- Vimeo
Add first review
Frequently asked
How much funding has AtaiBeckley raised?
AtaiBeckley has raised a total of $640M in funding. The most recent round on record is Merger.
How many employees does AtaiBeckley have?
AtaiBeckley has approximately 95 people on record.